FDA Reclassifies Imaging Tech for Needle-Guided Spinal Procedures
Published Date: 10/30/2026
Rule
Summary
The FDA is officially putting spinal imaging systems used in neuraxial procedures into Class II, meaning they’ll have special safety rules but less red tape than before. This change helps make sure these devices are safe and effective while speeding up patient access to new tech. The new classification took effect on October 30, 2026, but has been in place since January 19, 2024, so manufacturers should already be on board.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Specific testing and labeling requirements
Manufacturers must meet special controls including clinical performance testing (evaluating success rate, procedure time, adverse events like pain, bleeding, unintended dural puncture, injury, and comparison to manual palpation), non-clinical performance testing (accuracy, repeatability, resolution), human factors testing, software verification/validation (including image construction), electromagnetic/electrical/mechanical/thermal safety testing, biocompatibility of patient-contacting parts, sterility validation, and labeling that warns standard-of-care risks still apply.
Spinal imaging systems moved to Class II
The FDA classified spinal imaging systems for neuraxial procedures as Class II (special controls), effective October 30, 2026, and applicable January 19, 2024. FDA says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
Device remains subject to 510(k) filings
Spinal imaging systems for neuraxial procedures are subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act because FDA has not exempted this device type under section 510(m).
De Novo classification enables predicate use
FDA used the De Novo process to classify this device type; that De Novo classification can serve as a predicate for future devices of the same type, allowing other sponsors to use the 510(k) pathway instead of seeking De Novo or premarket approval.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22180, Medical Devices; Radiology Devices; Classification of the Radiology Software for Referral of Findings Related to Fibrotic Lung Disease
The FDA is officially putting radiology software that helps spot fibrotic lung disease into a safer, easier-to-manage category called Class II. This change, effective October 30, 2026, means the software will have special safety rules but face fewer hurdles, helping patients get access to new tech faster. Doctors, hospitals, and software makers will feel the impact, with smoother approval and no surprise costs.
Next: 2026-22182, Medical Devices; Anesthesiology Devices; Classification of the Over-the-Counter Device To Assess Risk of Sleep Apnea
The FDA is officially classifying over-the-counter devices that check your risk for sleep apnea as Class II, meaning they have special safety rules but are easier to get to help more people. This change, effective October 30, 2026, makes these devices safer and more accessible without heavy red tape. If you make or use these devices, expect smoother approval and better access starting now!